transparent gif

 

Ej inloggad.

Göteborgs universitets publikationer

Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection

Författare och institution:
Karin Önnheim (Institutionen för biomedicin, avdelningen för infektionssjukdomar); Maria Ekblad (Institutionen för biomedicin, avdelningen för infektionssjukdomar); Staffan Görander (Institutionen för biomedicin, avdelningen för infektionssjukdomar); Tomas Bergström (Institutionen för biomedicin, avdelningen för infektionssjukdomar); Jan-Åke Liljeqvist (Institutionen för biomedicin, avdelningen för infektionssjukdomar)
Publicerad i:
Viruses-Basel, 8 ( 4 )
ISSN:
1999-4915
Publikationstyp:
Artikel, refereegranskad vetenskaplig
Publiceringsår:
2016
Språk:
engelska
Fulltextlänk:
Sammanfattning (abstract):
Herpes simplex virus 2 (HSV-2) infects the genital mucosa and establishes a life-long infection in sensory ganglia. After primary infection HSV-2 may reactivate causing recurrent genital ulcerations. HSV-2 infection is prevalent, and globally more than 400 million individuals are infected. As clinical trials have failed to show protection against HSV-2 infection, new vaccine candidates are warranted. The secreted glycoprotein G (sgG-2) of HSV-2 was evaluated as a prophylactic vaccine in mice using two different immunization and adjuvant protocols. The protocol with three intramuscular immunizations combining sgG-2 with cytosine-phosphate-guanine dinucleotide (CpG) motifs and alum induced almost complete protection from genital and systemic disease after intra-vaginal challenge with HSV-2. Robust immunoglobulin G (IgG) antibody titers were detected with no neutralization activity. Purified splenic CD4+ T cells proliferated and produced interferon-gamma (IFN-gamma) when re-stimulated with the antigen in vitro. sgG-2 + adjuvant intra-muscularly immunized mice showed a significant reduction of infectious HSV-2 and increased IFN-gamma levels in vaginal washes. The HSV-2 DNA copy numbers were significantly reduced in dorsal root ganglia, spinal cord, and in serum at day six or day 21 post challenge. We show that a sgG-2 based vaccine is highly effective and can be considered as a novel candidate in the development of a prophylactic vaccine against HSV-2 infection.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP ->
Medicinska grundvetenskaper ->
Mikrobiologi inom det medicinska området ->
Mikrobiologi ->
Virologi
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin ->
Infektionsmedicin
Nyckelord:
secreted glycoprotein G, herpes simplex virus 2, vaccination, type-2 infection, monoclonal-antibodies, subunit vaccine, human-sera, b-cells, hsv-2, mice, antigen, identification, efficacy, Virology
Postens nummer:
236916
Posten skapad:
2016-05-25 14:45
Posten ändrad:
2016-05-25 14:45

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007